Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8071577 | BAYER HLTHCARE | Multi-phase contraceptive preparation based on a natural estrogen |
May, 2026
(3 years from now) | |
US8153616 | BAYER HLTHCARE | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
Jan, 2028
(4 years from now) |
Market Authorisation Date: 06 May, 2010
Treatment: Prevention of pregnancy; Treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception
Dosage: TABLET;ORAL
8
United States
7
European Union
4
Austria
4
Poland
4
Spain
4
Germany
4
Cyprus
4
Slovenia
4
Portugal
4
Denmark
3
Korea, Republic of
3
Japan
3
Argentina
3
Peru
3
Taiwan, Province of China
2
Uruguay
2
Croatia
2
China
2
ME
2
Canada
1
Hong Kong
1
RS
1
Brazil
1
Australia
1
Chile
1
Malaysia
1
Guatemala
1
Ukraine
1
Dominican Republic
1
Israel
1
Mexico
1
South Africa
1
El Salvador
1
EA
1
Panama
1
Norway
1
New Zealand
1
Costa Rica
1
Ecuador
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic